Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-FAPI-RGD in Metastatic Tumors
NCT06638034Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2024
- Primary completion
- Jan 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-FAPI-RGD in tumor, sponsored by Peking Union Medical College Hospital. Primary endpoints: Standardized Uptake Value at 6 months and Adverse Events Collection at 2 months. Started May 2024; status: recruiting.
02
Drugs
177Lu-FAPI-RGD
03
Conditions
tumor
Beyond the preview
Go deeper on NCT06638034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06638034.